In 2005, a 37-year-old finance professional named Anne Shimabukuro faced a pancreatic cancer diagnosis while raising two young daughters. Today, marking twenty years as a survivor, volunteer, and advocate with the Pancreatic Cancer Action Network (PanCAN), her journey highlights both the evolution of disease management and the ongoing work required to expand patient options.
Following her diagnosis, Shimabukuro underwent surgery, chemotherapy, and radiation after her oncologist directed her to PanCAN for reliable information. She subsequently connected with other survivors and volunteers through the organization’s Washington, D.C., area affiliate and participated in the region’s first PanCAN PurpleStride alongside her husband, John, and their daughters. Her involvement expanded to organizing hospitality for the event and engaging in advocacy efforts by meeting with members of Congress to call for increased federal research investment.
Research Review and Advocacy Efforts
Shimabukuro acknowledges that her long-term survival is an exception, noting that the majority of diagnosed individuals face poorer outcomes. To support broader progress, she has spent the past three years reviewing Department of Defense pancreatic cancer research grant proposals. While she remains encouraged by the scope of investigator proposals, she has expressed concern that promising scientific projects may remain unfunded without sufficient financial backing.
Advances in Scientific Possibilities
Reflecting on two decades since her initial diagnosis, Shimabukuro notes a landscape of expanded possibilities for patients. During a recent PanCAN Scientific Summit, she reviewed emerging developments discussed by researchers, which included early detection methods, blood-based tests, personalized medicine, and emerging treatments such as RAS inhibitors.
Yet it remains unstated whether current funding streams will expand rapidly enough to support all the promising research proposals currently submitted for grants.
